06:33:38 EDT Fri 25 Sep 2020
Enter Symbol
or Name

Login ID:
ChroMedX Corp
Symbol CHX
Shares Issued 80,416,223
Close 2018-03-19 C$ 0.40
Recent Sedar Documents

ChroMedX appoints Kailasanathan EVP, corporate finance

2018-03-19 16:13 ET - News Release

Mr. Clark Kent reports


ChroMedX Corp. has appointed Raj Kailasanathan as executive vice-president, corporate finance.

Mr. Kailasanathan joins ChroMedX as a seasoned finance executive with over 20 years experience in the private and public industry in Asia and North America. Prior to joining ChroMedX, Mr. Kailasanathan was chief financial officer at the innovative Toronto-based medical devices product development and contract manufacturing organization, Kangaroo Group, where he led finance and accounting functions and was instrumental in preparing the company for sale in April, 2017, to Starfish Medical.

"It is a great pleasure to welcome Raj to ChroMedX as part of our expanded executive team. He will play a crucial role in the management and strategy of financial operations as ChroMedX grows," said Lahav Gil, chief executive officer and director, ChroMedX.

Prior to joining Kangaroo, Mr. Kailasanathan acted as director of finance and corporate treasurer at Toronto Stock Exchange-listed company Real Matters Inc.

"I am thrilled to have the opportunity to be part of the team and to contribute to the growth and evolution of ChroMedX," said Mr. Kailansanathan, EVP corporate finance, ChroMedX. "This is an exciting time for all involved and I'd like to thank Lahav and the board of directors for this appointment."

About Raj Kailasanathan

Mr. Kailasanathan is a seasoned finance professional with more than 24 years of progressive experience in Asia and North America. Over the last 10 years, Mr. Kailasanathan has served in executive positions for several companies in the medtech and fintech sectors.

Prior to joining ChroMedX, Mr. Kailasanathan was the CFO at Kangaroo Group where he led the finance and accounting functions for the company. His insight, relationship management and negotiating skills assisted in the growth of the company, which eventually lead to its sale in April, 2017. Prior to Kangaroo Group, Mr. Kailasanathan was director of finance and corporate treasurer at the TSX-listed company Real Matters Inc.

Mr. Kailasanathan is committed and passionate about maximizing long-term shareholder value, entrepreneurism, innovation, growth initiatives, and maintaining a high level of integrity and transparency.

The company also announces that it has granted an aggregate of 300,000 options to purchase common shares of the company exercisable at today's closing price per share and expiring on March 20, 2023, to certain directors, officers and consultants of the company.

ChroMedX news and disclosure

Parties interested in keeping abreast of latest news and updates can subscribe on the home and news pages on the company's website.

About ChroMedX Corp.

ChroMedX is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the company's issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.

We seek Safe Harbor.

© 2020 Canjex Publishing Ltd. All rights reserved.